Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors)

Current Hepatitis Reports

, Volume 11, Issue 3, pp 146-152

First online:

Non-interferon Therapies for Hepatitis C

  • Fernando E. MembrenoAffiliated withAlamo Medical Research
  • , Eric J. LawitzAffiliated withAlamo Medical Research Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Hepatitis C (HCV) therapy is currently undergoing a revolution with the development of new classes of Direct Acting Antivirals (DAAs) with distinct mechanisms of action, potency, resistance patterns and significantly less side effects compared to current standard of care therapies. Our patients have struggled with interferon based therapies for the last 2 decades, but now we are at a turning point with the development of new non-interferon combinations of DAAs. These new molecules have demonstrated to be effective, safe and most importantly have shown the capacity to achieve a sustained virological response in the absence of interferon. This article summarizes the available published clinical trials that are rapidly contributing to our understanding of how we might need to combine these new antivirals to achieve the highest rates of cure in HCV patients who are treatment naïve, non-responders or cirrhotic, across all genotypes.


Interferon-free Non-interferon Interferon intolerant Ribavirin HCV Hepatitis C Direct acting antivirale DAA Tegobuvir GS-9190 RG7128 Danoprevir BI201335 BI207127 Alisporivir GS-5885 GS-9451 ABT-450/r ABT-072 ABT-333 Ritonavir Daclatasvir GS-7977 Asunaprevir DAAs